Ensign Peak Advisors’s ImmunityBio IBRX Stock Holding History

Ensign Peak Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$183K	Buy	+20,850	New	+$158K	﹤0.01%	1429
2025 Q1	–	Sell	-62,150	Closed	-$159K	–	1702
2024 Q4	$159K	Buy	62,150 +2,500	+4%	+$10.4K	﹤0.01%	1699
2024 Q3	$222K	Hold	59,650	–	–	﹤0.01%	1690
2024 Q2	$377K	Hold	59,650	–	–	﹤0.01%	1660
2024 Q1	$320K	Buy	+59,650	New	+$270K	﹤0.01%	1684
2022 Q4	–	Sell	-57,690	Closed	-$287K	–	1978
2022 Q3	$287K	Sell	57,690 -42,460	-42%	-$193K	﹤0.01%	1728
2022 Q2	$373K	Buy	100,150 +79,300	+380%	+$319K	﹤0.01%	1581
2022 Q1	$117K	Buy	20,850 +16,290	+357%	+$99.9K	﹤0.01%	1997
2021 Q4	$28K	Buy	+4,560	New	+$34.3K	﹤0.01%	2172

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ensign Peak Advisors's IBRX Position: Q2 2026 in Review

Ensign Peak Advisors opened a new position in ImmunityBio (IBRX) in Q2 2026: 20,850 shares worth $183K. The stake represents ﹤0.01% of the portfolio and ranks #1429 among its holdings. This is a return to the name: Ensign Peak Advisors previously reported a position in IBRX as recently as Q4 2024.

Ensign Peak Advisors first reported a position in IBRX in Q4 2021 and has held it in 9 quarters since. The position peaked at $377K in Q2 2024. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Ensign Peak Advisors held 20,850 shares of ImmunityBio worth $183K as of Q2 2026.
ImmunityBio was a new Ensign Peak Advisors position in Q2 2026.
ImmunityBio made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1429 holding.
Ensign Peak Advisors first reported a position in ImmunityBio in Q4 2021 and has held it in 9 quarters since.
Ensign Peak Advisors's ImmunityBio position peaked at $377K in Q2 2024.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.